Skip to main content

Commodore Capital LP

SEC CIK
0001831942
Latest filing
Aug 14, 2026

CLDX holding history

Celldex Therapeutics, Inc. in every 13F filed by Commodore Capital LP, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.

CLDX overviewAll 13F holders of CLDXFull Q2 2026 holdings

Shares (Q2 2026)
1,350,000
Value
$50.2M
% of portfolio
3.0%
Quarters held
20
Since Q1 2021
Holdings of CLDX by Commodore Capital LP, by quarter
QuarterSharesValue% of portfolioShare changeActionAll holders
Q2 20261,350,000$50.2M3.0%−1,346,616−49.9%ReducedHolders
Q1 20262,696,616$85.5M4.9%+131,616+5.1%AddedHolders
Q4 20252,565,000$69.7M4.6%−463,335−15.3%ReducedHolders
Q3 20253,028,335$78.3M3.8%−421,665−12.2%ReducedHolders
Q2 20253,450,000$70.2M5.0%+250,000+7.8%AddedHolders
Q1 20253,200,000$58.1M4.3%+3,200,000NewHolders
Q4 20240$00.0%−1,618,937−100.0%Sold outHolders
Q3 20241,618,937$55.0M3.4%+193,937+13.6%AddedHolders
Q2 20241,425,000$52.7M3.6%+558,532+64.5%AddedHolders
Q1 2024866,468$36.4M2.4%+164,501+23.4%AddedHolders
Q4 2023701,967$27.8M2.4%−4,698−0.7%ReducedHolders
Q3 2023706,665$19.4M2.3%+75,000+11.9%AddedHolders
Q2 2023631,665$21.4M2.4%+135,842+27.4%AddedHolders
Q1 2023495,823$17.8M2.7%00.0%UnchangedHolders
Q4 2022495,823$22.1M3.3%−42,989−8.0%ReducedHolders
Q3 2022538,812$15.1M2.4%00.0%UnchangedHolders
Q2 2022538,812$14.5M3.1%+297,613+123.4%AddedHolders
Q1 2022241,199$8.21M1.8%+241,199NewHolders
Q4 20210$00.0%−248,207−100.0%Sold outHolders
Q3 2021248,207$13.4M3.5%−75,230−23.3%ReducedHolders
Q2 2021323,437$10.8M3.8%−46,514−12.6%ReducedHolders
Q1 2021369,951$7.62M3.0%––Holders

Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.